Genmab A/S
OTC: GNMSF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jan van de Winkel
- Employees
- 2,638
- Headquarters
- Copenhagen, Denmark
- IPO year
- 2010
- Market cap
- $15.8B
- Website
- https://www.genmab.com
Loading GNMSF…
Loading profile data…Frequently asked questions about GNMSF
What does Genmab A/S (GNMSF) do?
Genmab A/S, founded in 1999 and based in Copenhagen, Denmark, is a biopharmaceutical firm focused on developing antibody-based therapeutics to treat cancer and a range of other diseases. The company markets several key products, including DARZALEX (daratumumab) for multiple myeloma, teprotumumab for thyroid eye disease, ofatumumab to address chr...
Where does GNMSF trade?
Genmab A/S (GNMSF) trades on the Other OTC.
What sector is GNMSF in?
Genmab A/S (GNMSF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Genmab A/S?
Jan van de Winkel is the chief executive officer of Genmab A/S (GNMSF).
Where is Genmab A/S headquartered?
Genmab A/S is headquartered in Denmark.
Does GNMSF pay a dividend?
Genmab A/S (GNMSF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did GNMSF go public?
Genmab A/S (GNMSF) completed its initial public offering in 2010.